August 19, 2021 12:47 PM EDTUpdated August 21, 11:53 AM

As Curia expands, it will add API site in upstate New York; In battle against food allergies, Alladapt to build site to prep for PhIII trials

Josh Sullivan

In July, contract manufacturer AMRI rebranded as Curia, and wrangled two biotechs to aid in its move toward global expansion. Thursday, the company announced that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Curia expands, it will add API site in upstate New York; In battle against food allergies, Alladapt to build site to prep for PhIII trials

Josh Sullivan

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Rare disease biopharma companies weigh in on FDA's new innovation hub

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

As Cu­ria ex­pands, it will add API site in up­state New York; In bat­tle against food al­ler­gies, Al­ladapt to build site to prep for PhI­II tri­als

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

As Curia expands, it will add API site in upstate New York; In battle against food allergies, Alladapt to build site to prep for PhIII trials